natgillin/translations-raw huggingface dataset:
In most cases these are mild reactions but some serious reactions can happen. 
V večini primerov so te reakcije blage, toda razvijejo se lahko tudi nekatere resne reakcije.
In rare cases, some of these infections were fatal. 
V redkih primerih so bile nekatere teh okužb smrtne.
Contraception for women 
Kontracepcija za ženske
· you are taking medicines for high blood pressure. 
• če jemljete zdravila proti visokemu krvnemu tlaku.
Store in a refrigerator 
Shranjujte v hladilniku
Age 18-55 years, EDSS of 3.0 to 6.5 
Starost od 18 do 55 let, EDSS od 3,0 do 6,5
Infusion 2 (2 weeks later) 
2. infundiranje (2 tedna pozneje)
Log-rank test 
Test log-rang
· low levels of a type of white blood cell (neutropenia) 
• nizke vrednosti določene vrste belih krvnih celic (nevtropenija)
Antibodies work by attaching to specific targets in your body. 
Protitelesa delujejo tako, da se v telesu vežejo na specifične cilje.
The capacity of B-cell reconstitution and preexisting humoral immunity are preserved. 
Sposobnost za rekonstitucijo celic B in obstoječa humoralna imunost se ohranita.
· This medicine is available in packs containing 1 or 2 vials (vials of 10 mL concentrate). 
• To zdravilo je na voljo v pakiranjih, ki vsebujejo 1 ali 2 viali (viale z 10 ml koncentrata).
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 8 January 2018 
Datum prve odobritve: 8. januar 2018
Pack size of 1 or 2 vials. 
Pakiranja z 1 ali 2 vialama.
Your blood B-cells will gradually increase to normal levels. 
Število celic B v krvi se vam bo polagoma povečalo na normalno raven.
A hypersensitivity reaction could also occur (acute allergic reaction to medicinal product). 
Pojavi se lahko preobčutljivostna reakcija (akutna alergijska reakcija na zdravilo).
· Keep this leaflet.You may need to read it again. 
Morda ga boste želeli ponovno prebrati.
10 mL concentrate in a glass vial. 
10 ml koncentrata v stekleni viali.
Patients over 55 years of age were not studied. 
Pri bolnikih, starejših od 55 let, raziskav niso opravili.
There have been no studies performed with other routes of administration. 
Študij o drugih poteh uporabe niso izvedli.
No formal pharmacokinetic study has been conducted. 
Formalnih farmakokinetičnih študij niso izvedli.
Some of them might be serious 
Nekatere od teh okužb so lahko resne.
Ocrevus (see section 4.3). 
Ocrevus (glejte poglavje 4.3).
· This medicine is not to be used after the expiry date which is stated on the outer carton and the vial label after ‘EXP'. 
• Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na zunanji ovojnini in nalepki viale poleg oznake "EXP".
Delayed or Missed Doses 
Zapozneli ali izpuščeni odmerki
When the reaction has stopped, the infusion may be continued. 
Ko reakcija mine, se infundiranje lahko nadaljuje.
Demographic and baseline characteristics were well balanced across the two treatment groups. 
Demografske in izhodiščne značilnosti so bile med terapevtskima skupinama dobro uravnotežene.
What is Multiple Sclerosis 
Kaj je multipla skleroza
· It is important to continue your treatment for as long as you and your doctor decide that it is helping you. 
• Pomembno je, da zdravljenje nadaljujete tako dolgo, kolikor časa zdravnik meni, da vam koristi.
Animal studies (embryo-foetal toxicity) do not indicate teratogenic effects. 
Študije na živalih (glede embrio-fetalne toksičnosti) niso pokazale teratogenih učinkov.
Non-confirmatory p-value; hierarchical testing procedure terminated before reaching endpoint. 
Nekonfirmativna analiza vrednosti p; hierarhični postopek testiranja se je končal, preden je bil dosežen opazovani dogodek.
The safety and timing of vaccination should be discussed with the infant's physician (see section 4.6). 
O varnosti in času cepljenja se je treba pogovoriti z dojenčkovim zdravnikom (glejte poglavje 4.6).
Clinical trial data have shown an association between decreased levels of IgG (and less so for IgM or IgA) and serious infections. 
Podatki iz kliničnih preskušanj so pokazali povezavo med znižanimi vrednostmi IgG (in manj za IgM ali IgA) in resnimi okužbami.
Patients with primary progressive form of MS 
Bolniki s primarno progresivno obliko MS
Multiple Sclerosis (MS) affects the central nervous system, especially the nerves in the brain and spinal cord. 
Multipla skleroza prizadene osrednje živčevje, zlasti živce v možganih in hrbtenjači.
Ocrevus should be avoided during pregnancy unless the potential benefit to the mother outweighs the potential risk to the foetus. 
Zdravilu Ocrevus se je treba med nosečnostjo izogibati, razen če možna korist za mater odtehta možno tveganje za plod.
CA 95688 
CA 95688 Združene države Amerike
Pharmacokinetics in Special Populations 
Farmakokinetika pri posebnih populacijah
The studies enrolled patients with active disease. 
V študije so bili vključeni bolniki z aktivno boleznijo.
· To get the full benefit of Ocrevus, it is important that you receive each infusion when it is due. 
• Da boste v polni meri deležni koristi zdravila Ocrevus, je pomembno, da vsako infuzijo dobite takrat, ko je čas zanjo.
An increase in the rate of serious infections was observed in RMS between Years 2 and 3, but not in subsequent years. 
Pri RMS so med 2. in 3. letom opažali večji delež resnih okužb, v poznejših letih pa ne.
Considering the first report of hepatitis B reactivation published for ocrelizumab and described in the previous PSUR, the PRAC recommended a minor revision of the statements in section 4.4 of the SmPC on the risk of hepatitis B reactivation. 
Ob upoštevanju prvega poročila o reaktivaciji hepatitisa B, objavljenega za okrelizumab in opisanega v prejšnjem PSUR, je odbor PRAC priporočil manjši popravek navedb o tveganju reaktivacije hepatitisa B v poglavju 4.4 SmPC.
4.5 Interaction with other medicinal products and other forms of interaction No formal drug interaction studies have been performed, as no drug interactions are expected via cytochrome P450 enzymes, other metabolising enzymes or transporters. 
4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Formalnih študij medsebojnega delovanja niso izvedli, ker ni pričakovati medsebojnega delovanja zdravil preko encimov citokroma P450, drugih presnovnih encimov ali prenašalcev.
The European Medicines Agency has deferred the obligation to submit the results of studies with Ocrevus in one or more subsets of the paediatric population in the treatment of multiple sclerosis. 
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Ocrevus za eno ali več podskupin pediatrične populacije za zdravljenje multiple skleroze.
EU/1/17/1231/002 
EU/1/17/1231/001 EU/1/17/1231/002
If an infusion of Ocrevus is missed, it should be administered as soon as possible; do not wait until the next planned dose. 
V primeru izpuščenega infundiranja zdravila Ocrevus je treba zdravilo uporabiti čim prej; ne čakajte do naslednjega načrtovanega odmerka.
· If you have an infusion-related reaction, you will be given medicines to treat it and the infusion may need to be slowed down or stopped. 
• Če imate z infuzijo povezano reakcijo, boste za njeno zdravljenje dobili zdravila, infundiranje pa bo morda treba upočasniti ali končati.
How much and how often you will be given Ocrevus 
Koliko zdravila Ocrevus boste prejemali in kako pogosto
· If you have any further questions, ask your doctor. 
• Če imate dodatna vprašanja, se posvetujte z zdravnikom.
· Your doctor may recommend that you are given a seasonal influenza vaccine. 
• Zdravnik vam bo morda priporočil, da se cepite s sezonskim cepivom proti gripi.
Proportion of patients with No Evidence of Disease Activity (NEDA) 
Delež bolnikov brez znakov aktivnosti bolezni (NEDA - No Evidence of Disease Activity)
The effect on the immune system of these medicines with Ocrevus could be too strong. 
Vpliv teh zdravil na imunski sistem bi bil skupaj z zdravilom Ocrevus lahko premočan.
Ocrevus also significantly increases the chance of a patient having no evidence of disease activity (brain lesions, relapses and worsening of disability). 
Zdravilo Ocrevus tudi pomembno poveča možnost, da bolnik ne bo imel nobenih znakov bolezenske aktivnosti (možganskih lezij, recidivov in poslabšanja prizadetosti).
Please see section 4.2 for populations not studied. 
Glejte poglavje 4.2 za neraziskane populacije.
This is because it has not yet been studied in this age group. 
Zdravilo namreč v tej starostni skupini ni raziskano.
Ocrevus will be given to you by a doctor or nurse who is experienced in the use of this treatment. 
Zdravilo Ocrevus vam bo dal zdravnik ali medicinska sestra, ki ima izkušnje z uporabo tega zdravila.
An increase in incidence was observed between years 3 and 4 of treatment due to basal cell carcinoma, which was not observed in subsequent years. 
Povečanje pojavnosti so opažali med 3. in 4. letom zdravljenja, in sicer zaradi bazalnoceličnega karcinoma, a to v naslednjih letih ni bilo opazno.
Patients with baseline score < 2 were not included in analysis. 
Bolniki z izhodiščno oceno < 2 niso bili vključeni v analizo.
Dilution will be done by a healthcare professional. 
Razredčenje bo opravilo zdravstveno osebje.
See under ‘Other medicines and Ocrevus', below for more information. 
Za več informacij glejte "Druga zdravila in zdravilo Ocrevus", spodaj.
Physicians should be vigilant for the early signs and symptoms of PML, which can include any new onset, or worsening of neurological signs or symptoms, as these can be similar to MS disease. 
Zdravniki morajo biti pozorni na zgodnje znake in simptome PML, ki lahko obsegajo katere koli novonastale nevrološke znake ali simptome ali njihovo poslabšanje, ker so lahko podobni multipli sklerozi.
If the infusion-related reaction is life-threatening, your doctor will permanently stop your treatment with Ocrevus. 
Če je z infuzijo povezana reakcija življenjsko ogrožajoča, bo zdravnik trajno končal vaše zdravljenje z zdravilom Ocrevus.
· if you are allergic to ocrelizumab or any of the other ingredients of this medicine (listed in section 6). 
• če ste alergični na okrelizumab ali katero koli sestavino tega zdravila (navedeno v poglavju 6),
Dose Modifications during Treatment 
Prilagoditev odmerka med zdravljenjem
In the controlled period of the clinical trials, the incidence of non-melanoma skin cancers was low and there was no imbalance between treatment groups. 
V kontroliranem obdobju kliničnih preskušanj je bila pojavnost nemelanomskih rakov kože majhna in med terapevtskimi skupinami ni bilo neravnovesij.
It is recommended to vaccinate patients treated with Ocrevus with seasonal influenza vaccines that are inactivated. 
Priporočljivo je, da bolnike, zdravljene z zdravilom Ocrevus, cepite s sezonskimi cepivi proti gripi, ki so inaktivirana.
This is because Ocrevus may pass into breast milk. 
Zdravilo Ocrevus namreč lahko prehaja v materino mleko.
Patients who require vaccination should complete their immunisation at least 6 weeks prior to initiation of Ocrevus. 
Bolniki, ki potrebujejo cepljenje, morajo imunizacijo dokončati vsaj 6 tednov pred uvedbo zdravila Ocrevus.
Other medicines and Ocrevus 
Druga zdravila in zdravilo Ocrevus
In PPMS, patients with swallowing difficulties are at a higher risk of aspiration pneumonia. 
Pri bolnikih s PPMS, ki imajo težave s požiranjem, obstaja večje tveganje za aspiracijsko pljučnico.
The final drug concentration after dilution is approximately 1.2 mg/mL. 
Končna koncentracija zdravila po razredčenju je približno 1,2 mg/ml.
Ocrevus is not intended to be used in children and adolescents under 18 years old. 
Zdravilo Ocrevus ni namenjeno uporabi pri otrocih in mladostnikih, mlajših od 18 let.
No dose reductions of Ocrevus are recommended. 
Zmanjšanja odmerka zdravila Ocrevus niso priporočena.
· Tell your doctor before being given Ocrevus if you are pregnant, think that you might be pregnant or are planning to have a baby. 
• Preden dobite zdravilo Ocrevus, morate zdravniku povedati, če ste noseči, menite, da bi lahko bili noseči ali načrtujete zanositev.
Patients should follow standard breast cancer screening per local guidelines. 
Bolnice se morajo udeleževati standardnih presejalnih pregledov za raka dojke v skladu z lokalnimi smernicami.
The precise mechanisms through which ocrelizumab exerts its therapeutic clinical effects in MS is not fully elucidated but is presumed to involve immunomodulation through the reduction in the number and function of CD20-expressing B cells. 
Natančni mehanizmi, po katerih okrelizumab doseže terapevtske klinične učinke pri multipli sklerozi, niso povsem pojasnjeni, a domnevno vključujejo imunomodulacijo z zmanjšanjem števila in funkcije celic B, ki imajo izražen CD20.
How does Ocrevus work? 
Kako deluje zdravilo Ocrevus?
· From a microbiological point of view, the prepared infusion should be used immediately. 
• Z mikrobiološkega stališča je treba pripravljeno infuzijo uporabiti takoj.
· Tell your doctor if you have recently been given any vaccine or might be given a vaccine in the near future. 
• Zdravniku morate povedati, če ste pred nedavnim dobili kakršno koli cepivo ali ga boste morda dobili v kratkem.
This reduced rate should be maintained for at least 30 minutes. 
Manjšo hitrost infundiranja je treba ohraniti vsaj 30 minut.
· At the request of the European Medicines Agency; · Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached. 
• ob vsakršni spremembi sistema za obvladovanje tveganj, zlasti kadar je tovrstna sprememba posledica prejema novih informacij, ki lahko privedejo do znatne spremembe razmerja med koristmi in tveganji, ali kadar je ta sprememba posledica tega, da je bil dosežen pomemben mejnik (farmakovigilančni ali povezan z zmanjševanjem tveganja).
This leaflet was last revised in <{MM/YYYY}> Other sources of information 
Navodilo je bilo nazadnje revidirano {MM. LLLL} Drugi viri informacij
Your doctor may ask you to stop taking your blood pressure medicines for 12 hours before each Ocrevus infusion. 
Zdravnik vam lahko naroči, da zdravila proti visokemu krvnemu tlaku prenehate jemati 12 ur pred vsakim infundiranjem zdravila Ocrevus.
· Your doctor will check if you need any vaccinations before you start treatment with Ocrevus. 
• Zdravnik bo preveril, ali pred začetkom zdravljenja z zdravilom Ocrevus potrebujete kakršno koli cepljenje.
Water for Injection 
voda za injekcije
If PML is confirmed, treatment must be discontinued permanently. 
V primeru potrjene PML je treba zdravljenje trajno ukiniti.
From a microbiological point of view, the prepared infusion should be used immediately. 
Z mikrobiološkega stališča je treba pripravljeno infuzijo uporabiti takoj.
The overall safety profile of Ocrevus in Multiple Sclerosis is based on data from patients from pivotal clinical trials in MS (RMS and PPMS). 
Celotne varnostne značilnosti zdravila Ocrevus pri multipli sklerozi temeljijo na podatkih bolnikov iz ključnih kliničnih preskušanj pri multipli sklerozi (RMS in PPMS).
In case of IRRs during any infusion, see the following adjustments. 
V primeru z infuzijo povezanih reakcij med katerim koli infundiranjem glejte naslednje prilagoditve.
Breakdown of the myelin sheath stops the nerves working properly. 
Razgradnja mielinske ovojnice prepreči pravilno delovanje živcev.
Patients with a known active malignancy should not be treated with 
Bolniki z znano aktivno maligno boleznijo ne smejo prejemati zdravila
The extent and duration of B-cell depletion was consistent in the PPMS and RMS trials. 
Obseg in trajanje zmanjšanja števila celic B se je v preskušanjih pri PPMS in RMS skladalo.
This is because Ocrevus may lower blood pressure. 
Pri nekaterih bolnikih lahko namreč zdravilo Ocrevus zniža krvni tlak.
Prior to the start of the intravenous infusion, the content of the infusion bag should be at room temperature. 
Pred začetkom intravenskega infundiranja naj bo vsebina infuzijske vreče na sobni temperaturi.
Ocrevus treatment may further increase the risk of severe pneumonia in these patients. 
Zdravljenje z zdravilom Ocrevus lahko tem bolnikom dodatno poveča tveganje za pljučnico.
· Ocrevus will be given to you by a doctor or a nurse. 
• Zdravilo Ocrevus vam bo dal zdravnik ali medicinska sestra.
You will receive a corticosteroid and an anti-histamine before each infusion and you may also receive medicines to reduce fever. 
Pred vsakim infundiranjem boste dobili kortikosteroid in antihistaminik; morda boste dobili tudi zdravila za znižanje zvišane telesne temperature.
Analysis of patient populations with differing baseline levels of disease activity, including active and highly active disease, showed that the efficacy of Ocrevus on ARR and 12 week CDP was consistent with the overall population. 
Analiza populacij bolnikov z različnimi izhodiščnimi ravnmi aktivnosti bolezni, vključno z aktivno in zelo aktivno boleznijo, je pokazala, da je bila učinkovitost zdravila Ocrevus, kar zadeva preračunani delež recidivov na leto in 12-tedensko potrjeno napredovanje prizadetosti, skladna s celotno populacijo.
Constant clearance was estimated at 0.17 L/day, and initial time-dependent clearance at 0.0489 L/day which declined with a half-life of 33 weeks. 
Ocenjeni stalni očistek je 0,17 l/dan in ocenjeni uvodni od časa odvisni očistek 0,0489 l/dan, ki se je zmanjševal z razpolovnim časom 33 tednov.
Infections were predominantly mild to moderate in severity and patients recovered with treatment by standard therapies. 
Okužbe so bile pretežno blage do zmerne in bolniki so okrevali po uporabi običajnih načinov zdravljenja.
· Tell your doctor or nurse straight away if you think your MS is getting worse or if you notice any new symptoms. 
• Zdravniku ali medicinski sestri morate takoj povedati, če se vam zdi, da se vam multipla skleroza slabša, ali če opazite kakršen koli nov simptom.
· Before you start treatment with Ocrevus and before subsequent infusions, your doctor may ask you to have a blood test to verify your immune system because infections may occur more frequently in case of severe problems with your immune system. 
• Pred začetkom zdravljenja z zdravilom Ocrevus in pred nadaljnjimi infundiranji lahko zdravnik naroči preiskavo krvi, s katero preveri imunski sistem, kajti okužbe so lahko v primeru hudih težav z imunskim sistemom pogostejše.
The above examples of dose interruption and slowing (for mild/moderate and severe IRRs) will result in a change in the infusion rate and increase the total duration of the infusion, but not the total dose. 
Zgornji primeri prekinitve odmerka in upočasnitve (za blage/zmerne in hude z infuzijo povezane reakcije) spremenijo hitrost infundiranja in podaljšajo njegovo trajanje, ne spremenijo pa celotnega odmerka.
This is because the immune cells that Ocrevus targets also help to fight infection. 
Imunske celice, ki so cilj zdravila Ocrevus, namreč pomagajo tudi pri premagovanju okužb.
There is limited clinical trial experience with doses higher than the approved intravenous dose of Ocrevus. 
Iz kliničnih preskušanj je malo izkušenj z odmerki, večjimi od odobrenega intravenskega odmerka zdravila Ocrevus.
Relative Increase (Pooled Analysis1) Relative Increase (Individual Studies 
Relativno povečanje (kumulativna analiza Relativno povečanje (posamezna študija
The impact of treatment-emergent ADAs on safety and efficacy cannot be assessed given the low incidence of ADA associated with Ocrevus. 
Vpliva ADA, ki nastanejo med zdravljenjem, na varnost in učinkovitost ni mogoče oceniti glede na majhno pojavnost ADA, povezanih z zdravilom Ocrevus.
1 Symptoms reported as IRRs within 24 hours of the infusion are described below in ‘Infusion-related reactions'. 
Simptomi, zabeleženi kot z infuzijo povezane reakcije v 24 urah po infundiranju, so opisani v spodnjem odstavku "Z infuzijo povezane reakcije".
20.7% Ocrevus vs 15.6% IFN 
20,7 % zdravilo Ocrevus v primerjavi s 15,6 % IFN
Knowledge is limited as to whether concomitant steroid use for symptomatic treatment of relapses is associated with an increased risk of infections in clinical practice. 
Malo je znanega o tem, ali je sočasna uporaba steroidov za simptomatsko zdravljenje recidivov v klinični praksi povezana z večjim tveganjem za okužbe.
Patients with active HBV (i.e. an active infection confirmed by positive results for HBsAg and anti HB testing) should not be treated with Ocrevus. 
Bolnikov z aktivnim HBV (tj. z aktivno okužbo, potrjeno s pozitivnim rezultatom HBsAg in testiranjem anti-HB) se ne sme zdraviti z zdravilom Ocrevus.
Available pharmacodynamic/toxicological data in animals have shown excretion of ocrelizumab in milk (for details see section 5.3). 
Farmakodinamični/toksikološki podatki, ki so na voljo za živali, so pokazali, da se okrelizumab izloča v materino mleko (za podrobnosti glejte poglavje 5.3).
Percentage change in brain volume from Week 24 to week 96 Relative reduction in brain volume loss 
Odstotek spremembe volumna možganov od 24. do 96. tedna Relativno zmanjšanje izgube možganskega volumna
An exploratory analysis identified the following factors associated with risk of serious infections: higher doses of Ocrevus than recommended in MS, other comorbidities, and chronic use of immunosuppressants/corticosteroids. 
V eksploratorni analizi so zaznali naslednje dejavnike, povezane s tveganjem za resne okužbe: odmerki zdravila Ocrevus, večji od priporočenih pri multipli sklerozi, druge sočasne bolezni in kronična uporaba imunosupresivov/kortikosteroidov.
· Before you start any other medicines, tell your doctor when you had your last Ocrevus infusion. 
• Preden začnete uporabljati katero koli novo zdravilo, morate zdravniku povedati, kdaj ste prejeli zadnjo infuzijo zdravila Ocrevus.
It is recommended that the product is used immediately after dilution. 
Zdravilo je priporočljivo uporabiti takoj po razredčenju.
· While you are being treated with Ocrevus, you should not be given live or live attenuated vaccines (for example BCG for tuberculosis or vaccines against yellow fever). 
• Med zdravljenjem z zdravilom Ocrevus ne smete dobiti živih ali živih oslabljenih cepiv (na primer BCG proti tuberkulozi ali cepiv proti rumeni mrzlici).
The safety of immunisation with live or live-attenuated vaccines, following Ocrevus therapy has not been studied and vaccination with live-attenuated or live vaccines is not recommended during treatment and not until B-cell repletion (in clinical trials, the median time for B-cell repletion was 72 weeks). 
Varnost imunizacije z živimi ali živimi oslabljenimi cepivi po zdravljenju z zdravilom Ocrevus ni raziskana in cepljenje z živimi ali živimi oslabljenimi virusnimi cepivi med zdravljenjem in do ponovnega porasta števila celic B ni priporočljivo (v kliničnih preskušanjih je bil mediani čas do ponovnega porasta celic B 72 tednov).
· Infusion-related reactions are the most common side effect of Ocrevus treatment (very common: may affect more than 1 in 10 people). 
• Z infuzijo povezane reakcije so najpogostejši neželeni učinek zdravljenja z zdravilom Ocrevus (so zelo pogoste: pojavijo se lahko pri več kot 1 od 10 bolnikov).
· If you are treated with Ocrevus for primary progressive multiple sclerosis, and you have swallowing difficulties, Ocrevus may increase the risk of severe pneumonia. 
• Če prejemate zdravilo Ocrevus za zdravljenje primarno progresivne multiple skleroze in imate težave s požiranjem, lahko zdravilo Ocrevus poveča tveganje za hudo pljučnico.
Ocrevus has no or negligible influence on the ability to drive and use machines. 
Zdravilo Ocrevus nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Subsequent Doses (600 mg) once every 6 months 
(600 mg) enkrat na 6 mesecev
CD20 is a cell surface antigen found on pre-B cells, mature and memory B cells but not expressed on lymphoid stem cells and plasma cells. 
CD20 je antigen na celični površini, ki je prisoten na celicah pred-B in spominskih celicah B, ni pa izražen na limfatičnih matičnih celicah ali na plazmatkah.